AngioLab안지오랩
251280 · KONEX · ₩251280 · 안지오랩
- Market cap
- ₩8B
- Enterprise value
- —
- P/E
- —
- P/B
- —
- Dividend yield
- 0.0%
- ROE
- —
- Net margin
- —
Financial statements not available yet. Dividend yield: the 2025 dividend per share from the annual report ÷ today's price.
52-week range−52.9% from the high
₩1,523Today: ₩1,995 – ₩2,345₩4,635
Returns
- 1W−12.2%
- 1M−16.0%
- 3M+21.7%
- 6M+27.5%
- YTD−11.2%
- 1Y−44.0%
- Volume today
- 2,844
- 2.3× the 20-day average
- Traded today
- ₩5.7M
- Listed shares
- 3,658,532
- EPS (12 months)
- —
🎁 Gift this stock
Send a friend ₩100,000 of paper money in this stock. They get it when they join.
Why is it moving?
−6.8% on Oct 30, 2026. Trading value 2.0× its normal.
- • Buzz 55 on JONBUR: heavy trading
We found no news, filing or broker report explaining it yet. Moves without news happen; it may come later.
Possible reasons, not certainties. Not financial advice.
Signals
Normal- BuzzNormalBuzz 55: heavy trading.
- MomentumWeak-19.1% over the last month; the price is below its 20-day average.
- News impactLow1 news items and filings in two weeks; 0 rated high impact, 0 medium.
Signals describe activity, not recommendations. Not financial advice.
AngioLab stock overview
AngioLab (안지오랩, KRX: 251280) is listed on KONEX, in the Biotech & Pharma sector. The company is a Korean pharmaceutical and biopharmaceutical business centered on research, development, and manufacture of medicines, with focus areas described in its filing including natural-product drugs, antibody drugs, and biosimilars. Its shares closed at ₩2,185 on Oct 30, 2026, down 6.82% on the day, giving it a market value of ₩8B.
Key facts
- Market cap
- ₩8B
- Sector
- Biotech & Pharma
- Latest price change
- −6.82%
- As of
- Oct 30, 2026
- Main business
- The company is a Korean pharmaceutical and biopharmaceutical business centered on research, development, and manufacture of medicines, with focus areas described in its filing including natural-product drugs, antibody drugs, and biosimilars.
Quick answers about AngioLab
- What does AngioLab do?
- The company is a Korean pharmaceutical and biopharmaceutical business centered on research, development, and manufacture of medicines, with focus areas described in its filing including natural-product drugs, antibody drugs, and biosimilars. Its filing describes these products serving patients in global markets, with growing exports and technology licensing to international partners. The filing excerpt provided describes industry conditions in these areas and does not detail the company's own specific products, customers, or locations.
- What is the market cap of AngioLab?
- The market capitalisation of AngioLab was ₩8B at the close on Oct 30, 2026.
- Who are the largest shareholders of AngioLab?
- According to the latest official filings, the largest reported holders are Kim Min-young (20.40%, as of Sep 14, 2026); Shinhan Venture Investment (4.32%, as of Jan 22, 2026); Interbest (3.81%, as of Sep 10, 2025).
- When is the next earnings report from AngioLab?
- Korean companies rarely announce results dates in advance. Based on when AngioLab filed the same report in past years, its next annual results is expected between Mar 18, 2027 and Mar 20, 2027.
Company profile
The company is a Korean pharmaceutical and biopharmaceutical business centered on research, development, and manufacture of medicines, with focus areas described in its filing including natural-product drugs, antibody drugs, and biosimilars. Its filing describes these products serving patients in global markets, with growing exports and technology licensing to international partners. The filing excerpt provided describes industry conditions in these areas and does not detail the company's own specific products, customers, or locations.
Written by AI from the company's latest annual report.
- Korean name
- 안지오랩
- Sector
- Biotech & Pharma
- Themes
- Medical devices
- CEO
- 김민영
- Founded
- Jun 1999
- Listed
- Oct 2016
- Listed shares
- 3,658,532
- Fiscal year ends
- Month 12
- Website
- www.angiolab.co.kr
Similar companies
- Samsung Biologics207940 · ₩69T₩1,487,000+8.86%
- Celltrion068270 · ₩44T₩191,600+1.22%
- Alteogen196170 · ₩15T₩211,500−3.86%
- SK biopharmaceuticals326030 · ₩6.1T₩77,700−0.13%
- Yuhan000100 · ₩5.5T₩75,100+0.54%
- HLB028300 · ₩5.3T₩40,000+0.76%
- Hanmi Pharm128940 · ₩5.3T₩415,000+6.82%
- SAM Chun Dang Pharm000250 · ₩4.3T₩182,700−3.13%
Recent filings
See all- Investor relations (IR) eventOct 22, 2026
- Exercise of Conversion Rights of Convertible SharesSep 22, 2026
- Insider shareholding reportSep 14, 2026
- Insider shareholding reportSep 7, 2026
- Insider shareholding reportAug 31, 2026
Titles in Korean until English translations are added.
Also known as: AngioLab / 안지오랩 / 251280 / KRX:251280
Source: KRX statistical information